Abstract:Esophageal squamous cell carcinoma (ESCC) is one of most prevalent cancers worldwide, especially in China. Lacking in depth mechanism study, effective targets and therapeutics are desperately needed in the clinic. RNA-binding proteins (RBPs) mediate the localization, stability, and translation of the target transcripts and fine-tune the physiological functions of the proteins encoded. Bioinformatics analysis revealed that IGF2BPs were highly expressed in ESCC tissues and at least participated in the regulation of cell proliferation of ESCC cells. Biological researches demonstrated that IGF2BP2 promoted the cell proliferation, migration and invasion of ESCC KYSE30 and KYSE450 cells. IGF2BP2 could bind to EIF4A1 mRNA by recognition of m6A sites and enhanced translation of EIF4A1. IGF2BPs, as m6A reader, IGF2BPs were oncogenic genes in ESCC by regulating the expression of EIF4A1 through m6A sites. IGF2BP2, EIF4A1 and their targets could serve as potential biomarkers and therapeutic targets for ESCC, offering promising novel approaches for the diagnosis and treatment of ESCC.

What problem does this paper attempt to address?

The paper primarily explores the mechanism of IGF2BP2 in esophageal squamous cell carcinoma (ESCC) and its potential as a therapeutic target. Specifically, the study addresses the following key issues: 1. **Expression of IGF2BP2 and IGF2BP3 in ESCC**: Through bioinformatics analysis, it was found that IGF2BP2 and IGF2BP3 are significantly upregulated in ESCC samples, while the change in IGF2BP1 is not obvious. 2. **IGF2BP2 as a potential prognostic marker for ESCC**: Although no significant correlation between IGF2BP2 expression and survival was observed in ESCC patients, high expression of IGF2BP2 is associated with poor prognosis in other cancer types such as head and neck squamous cell carcinoma, pancreatic cancer, and endometrial cancer. This suggests that IGF2BP2 may also be a prognostic marker for ESCC. 3. **Impact of IGF2BP2 and IGF2BP3 on ESCC cell proliferation**: Using CRISPR-Cas9 high-throughput screening technology, it was demonstrated that IGF2BP2 and IGF2BP3 are growth-dependent genes in ESCC cells, and knocking down these genes can inhibit cell proliferation. 4. **Oncogenic role of IGF2BP2**: Experimental results show that IGF2BP2 can promote the migration and invasion of ESCC cells, and this effect may be related to its regulation of EIF4A1 translation. 5. **Relationship between IGF2BP2 and m6A modification**: The study found that IGF2BP2 binds to RNA molecules by recognizing m6A methylation in specific sequences, further revealing the mechanism of IGF2BP2 in the development of ESCC. In summary, this study aims to elucidate the role of IGF2BP2 in the pathogenesis of ESCC and explore its potential as a therapeutic target. Through a series of experiments, researchers confirmed that IGF2BP2 promotes the progression of ESCC by regulating the translation of EIF4A1, providing new insights for the diagnosis and treatment of ESCC.

The m6A reader IGF2BP2 promotes esophageal cell carcinoma progression by enhancing EIF4A1 translation